Helicobacter pylori infection and the risk of Barrett's oesophagus: A community-based study

Gut

Volumn 57, Issue 6, 2008, Pages 727-733

  Corley, D A ^a,b   Kubo, A ^a,c   Levin, T R ^a   Block, G ^d   Habel, L ^a   Zhao, W ^a   Leighton, P ^a   Rumore, G ^a   Quesenberry, C ^a   Buffler, P ^d   Parsonnet, J ^e  

^a DIVISION OF RESEARCH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Columbia University ^*  (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAGA PROTEIN;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; BODY MASS; CASE CONTROL STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; GASTROESOPHAGEAL REFLUX; HEALTH CARE DELIVERY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; IMMUNOASSAY; INTERVIEW; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; RISK FACTOR; SEROLOGY; UNITED STATES;

ADENOCARCINOMA; ADULT; AGED; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BARRETT ESOPHAGUS; CASE-CONTROL STUDIES; ESOPHAGEAL NEOPLASMS; FEMALE; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; PRECANCEROUS CONDITIONS; RISK ASSESSMENT;

EID: 44149114066     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2007.132068     Document Type: Article

References (70)

1. Blot WJ, McLaughlin JK. The changing epidemiology of esophageal cancer. Semin Oncol 1999;26(5 Suppl 15):2-8.
2. Bollschweiler E, Wolfgarten E, Gutschow C, et al. Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer 2001;92:549-55.
3. Corley D, Buffler P. Oesophageal and gastric cardia adenocarcinomas: analysis of regional variation using the Cancer Incidence in Five Continents database. Int J Epidemiol 2001;30:1415-25.
4. Kubo A, Corley DA. Marked regional variation in adenocarcinomas of the esophagus and the gastric cardia in the United States. Cancer 2002;95:2096-102.
5. Sharma P, McQuaid K, Dent J, et al. A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. Gastroenterology 2004;127:310-30.
6. Huang JQ, Zheng GF, Sumanac K, et al. Meta-analysis of the relationship between cagA seropositivity and gastric cancer. Gastroenterology 2003;125:1636-44.
7. Ye W, Held M, Lagergren J, et al. Helicobacter pylori infection and gastric atrophy: risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia. J Natl Cancer Inst 2004;96:388-96.
8. Wu AH, Crabtree JE, Bernstein L, et al. Bole of Helicobacter pylori CagA+ strains and risk of adenocarcinoma of the stomach and esophagus. Int J Cancer 2003;103:815-21.
9. de Martel C, Llosa AE, Farr SM, et al. Helicobacter pylori infection and the risk of development of esophageal adenocarcinoma. J Infect Dis 2005;191:761-7.
10. Chow WH, Blaser MJ, Blot WJ, et al. An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res 1998;58:588-90.
11. Go MF. Review article: natural history and epidemiology of Helicobacter pylori infection. Aliment Pharmacol Ther 2002;16(Suppl 1):3-15.
12. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998;83:2049-53.
13. Kubo A, Corley DA. Marked multi-ethnic variation of esophageal and gastric cardia carcinomas within the United States. Am J Gastroenterol 2004;99:582-8.
14. el-Serag HB, Sonnenberg A. Opposing time trends of peptic ulcer and reflux disease. Gut 1998;43:327-33.
15. Moayyedi P. Should we test for Helicobacter pylori before treating gastroesophageal reflux disease? Can J Gastroenterol 2005;19:425-7.
16. Johansson J, Hakansson HO, Mellblom L, et al. Risk factors for Barrett's oesophagus: a population-based approach. Scand J Gastroenterol 2007;42:148-56.
17. Ferrandez A, Benito R, Arenas J, et al. CagA-positive Helicobacter pylori infection is not associated with decreased risk of Barrett's esophagus in a population with high H. pylori infection rate. BMC Gastroenterol 2006;6:7.
18. Wong A, Fitzgerald RC. Epidemiologic risk factors for Barrett's esophagus and associated adenocarcinoma. Clin Gastroenterol Hepatol 2005;3:1-10.
19. Zhang J, Chen XL, Wang KM, et al. Relationship of gastric Helicobacter pylori infection to Barrett's esophagus and gastro-esophageal reflux disease in Chinese. World J Gastroenterol 2004;10:672-5.
20. Weston AP, Badr AS, Topalovski M, et al. Prospective evaluation of the prevalence of gastric Helicobacter pylori infection in patients with GERD, Barrett's esophagus, Barrett's dysplasia, and Barrett's adenocarcinoma. Am J Gastroenterol 2000;95:387-94.
21. Vaezi MF, Falk GW, Peek RM, et al. CagA-positive strains of Helicobacter pylori may protect against Barrett's esophagus. Am J Gastroenterol 2000;95:2206-11.
22. Lord BV, Frommer DJ, Inder S, et al. Prevalence of Helicobacter pylori infection in 160 patients with Barrett's oesophagus or Barrett's adenocarcinoma. Aust N Z J Surg 2000;70:26-33.
23. Vicari JJ, Peek RM, Falk GW, et al. The seroprevalence of cagA-positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease. Gastroenterology 1998;115:50-7.
24. Csendes A, Smok G, Cerda G, et al. Prevalence of Helicobacter pylori infection in 190 control subjects and in 236 patients with gastroesophageal reflux, erosive esophagitis or Barrett's esophagus. Dis Esophagus 1997;10:38-42.
25. Nelson DB, Murdoch M, Sandozi IK, et al. Dyspepsia is associated with CagA-positive Helicobacter pylori. Am J Gastroenterol 2000;95:3412-7.
26. Danesh J, Lawrence M, Murphy M, et al. Systematic review of the epidemiological evidence on Helicobacter pylori infection and nonulcer or uninvestigated dyspepsia. Arch Intern Med 2000;160:1192-8.
27. Graham DY, Lew GM, Klein PD, et al. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. Ann Intern Med 1992;116:705-8.
28. Cutler AF, Prasad VM, Santogade P. Four-year trends in Helicobacter pylori IgG serology following successful eradication. Am J Med 1998;105:18-20.
29. Gisbert JP, Blanco M, Benito LM, et al. Value of quantitative serology for confirmation of Helicobacter pylori eradication: an 18-month follow-up study. Clin Infect Dis 2000;30:976-80.
30. Kokkola A, Kosunen TU, Puolakkainen P, et al. Spontaneous disappearance of Helicobacter pylori antibodies in patients with advanced atrophic corpus gastritis. Apmis 2003;111:619-24.
31. Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 2001;49:347-53.
32. Krieger N. Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. Am J Public Health 1992;82:703-10.
33. Rothman KJ, Greenland S. Modern epidemiology. 2nd ed. Philadelphia: Lippincott-Raven, 1998.
34. Locke GR, Talley NJ, Weaver AL, et al. A new questionnaire for gastroesophageal reflux disease. Mayo Clin Proc 1994;69:539- 47.
35. Parsonnet J, Hansen S, Rodriguez L, et al. Helicobacter pylori infection and gastric lymphoma. N Engl J Med 1994;330:1267- 71.
36. Parsonnet J, Friedman GD, Vandersteen DP, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991;325:1127-31.
37. Parsonnet J, Replogle M, Yang S, et al. Seroprevalence of CagA-positive strains among Helicobacter pylori-infected, healthy young adults. J Infect Dis 1997;175:1240-2.
38. Parsonnet J, Friedman GD, Orentreich N, et al. Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection. Gut 1997;40:297-301.
39. Zhao Y, Ash AS, Ellis RP, et al. Predicting pharmacy costs and other medical costs using diagnoses and drug claims. Med Care 2005;43:34-43.
40. Zhao Y, Ellis RP, Ash AS, et al. Measuring population health risks using inpatient diagnoses and outpatient pharmacy data. Health Serv Res 2001;36:180-93.
41. Breslow NE, Day NE. Statistical methods in cancer research. Volume 1 - The analysis of case-control studies. Lyon: International Agency for Research on Cancer, 1980.
42. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic research. Principles and quantitative methods New York: Van Nostrand Reinhold, 1982.
43. Hosmer DW, Lemeshow S. Applied logistic eegression. 2nd ed. New York: John Wiley & Sons; 2000.
44. Greenland S, Drescher K. Maximum likelihood estimation of the attributable fraction from logistic models. Biometrics 1993;49:865-72.
45. Wu JC, Sung JJ, Chan FK, et al. Helicobacter pylori infection is associated with milder gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000;14:427-32.
46. Labenz J, Jaspersen D, Kulig M, et al. Risk factors for erosive esophagitis: a multivariate analysis based on the ProGERD study initiative. Am J Gastroenterol 2004;99:1652-6.
47. Koike T, Ohara S, Sekine H, et al. Helicobacter pylori infection prevents erosive reflux oesophagitis by decreasing gastric acid secretion. Gut 2001;49:330-4.
48. Webb PM, Crabtree JE, Forman D. Gastric cancer, cytotoxin-associated gene A-positive Helicobacter pylori, and serum pepsinogens: an international study. The Eurogst Study Group. Gastroenterology 1999;116:269-76.
49. Oksanen A, Sipponen P, Karttunen R, et al. Atrophic gastritis and Helicobacter pylori infection in outpatients referred for gastroscopy. Gut 2000;46:460-3.
50. McColl KE. Review article: Helicobacter pylori and gastro-oesophageal reflux disease - the European perspective. Aliment Pharmacol Ther 2004;20(Suppl 8):36-9.
51. Cremonini F, Di Caro S, Delgado-Aros S, et al. Meta-analysis: the relationship between Helicobacter pylori infection and gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2003;18:279-89.
52. Cremonini F, Di Caro S, Delgado-Aros S, et al. Meta-analysis: the relationship between Helicobacter pylori infection and gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2004;19:145.
53. Laine L, Sugg J. Effect of Helicobacter pylori eradication on development of erosive esophagitis and gastroesophageal reflux disease symptoms: a post hoc analysis of eight double blind prospective studies. Am J Gastroenterol 2002;97:2992-7.
54. Rowland M, Daly L, Vaughan M, et al. Age-specific incidence of Helicobacter pylori. Gastroenterology 2006;130:65-72; quiz 211.
55. Fennerty MB. Is nonulcer dyspepsia related to Helicobacter pylori infection? Semin Gastrointest Dis 2001;12:180-5.
56. El-Serag HB, Petersen NJ, Carter J, et al. Gastroesophageal reflux among different racial groups in the United States. Gastroenterology 2004;126:1692-9.
57. Rex DK, Cummings OW, Shaw M, et al. Screening for Barrett's esophagus in colonoscopy patients with and without heartburn. Gastroenterology 2003;125:1670-7.
58. Gerson LB, Shetler K, Triadafilopoulos G. Prevalence of Barrett's esophagus in asymptomatic individuals. Gastroenterology 2002;123:461-7.
59. Farrow DC, Vaughan TL, Sweeney C, et al. Gastroesophageal reflux disease, use of H2 receptor antagonists, and risk of esophageal and gastric cancer. Cancer Causes Control 2000;11:231-8.
60. Lagergren J, Bergstrom R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-31.
61. Sykora J, Malan A, Zahlava J, et al. Gastric emptying of solids in children with H. pylori-positive and H. pylori-negative non-ulcer dyspepsia. J Pediatr Gastroenterol Nutr 2004;39:246-52.
62. Lee J, O'Morain C. Who should be treated for Helicobacter pylori infection? A review of consensus conferences and guidelines. Gastroenterology 1997;113(6 Suppl):S99-106.
63. Shiotani A, Miyanishi T, Uedo N, et al. Helicobacter pylori infection is associated with reduced circulating ghrelin levels independent of body mass index. Helicobacter 2005;10:373-8.
64. Tatsuguchi A, Miyake K, Gudis K, et al. Effect of Helicobacter pylori infection on ghrelin expression in human gastric mucosa. Am J Gastroenterol 2004;99:2121-7.
65. Nwokolo CU, Freshwater DA, O'Hare P, et al. Plasma ghrelin following cure of Helicobacter pylori. Gut 2003;52:637-40.
66. Azuma T, Suto H, Ito Y, et al. Eradication of Helicobacter pylori infection induces an increase in body mass index. Aliment Pharmacol Ther 2002;16(Suppl 2):240-4.
67. Kubo A, Corley DA. Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2006;15:872-8.
68. Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 2005;143:199-211.
69. Kamangar F, Dawsey SM, Blaser MJ, et al. Opposing risks of gastric cardia and noncardia gastric adenocarcinomas associated with Helicobacter pylori seropositivity. J Natl Cancer Inst 2006;98:1445-52.
70. Morrison AS. Screening in chronic disease. 2nd ed. New York: Oxford University Press, 1992.